Global Hemophilia Gene Therapy Market Size, Status and Forecast 2019-2025
Hemophilia is an ideal genetic disorder and the drawbacks with the majority of the standard protein substitution therapy drugs resulted in the shift in interest towards the development of alternative treatments by gene therapy.
Though the risk of developing antibodies to the viral vectors that are used to deliver the genetic material to the cells poses as a major drawback to gene therapy, the rising commercial importance of the gene therapy approach for the treatment of hemophilia resulted in a rise in the number of collaboration agreements between industries and research institutes. For instance, the acquisition of Baxalta helped the specialty pharmaceutical company become the largest hemophilia player and the company has announced that it has generated a revenue of more than USD 870 million in 2017.
In 2018, the global Hemophilia Gene Therapy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Hemophilia Gene Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hemophilia Gene Therapy development in United States, Europe and China.
The key players covered in this study
uniQure
Alnylam Pharmaceuticals
BioMarin Pharmaceutical
Spark Therapeutics
Shire
...
Market segment by Type, the product can be split into
Monotherapy
Combination Therapy
Market segment by Application, split into
Hemophilia A
Hemophilia B
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Hemophilia Gene Therapy status, future forecast, growth opportunity, key market and key players.
To present the Hemophilia Gene Therapy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Hemophilia Gene Therapy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Though the risk of developing antibodies to the viral vectors that are used to deliver the genetic material to the cells poses as a major drawback to gene therapy, the rising commercial importance of the gene therapy approach for the treatment of hemophilia resulted in a rise in the number of collaboration agreements between industries and research institutes. For instance, the acquisition of Baxalta helped the specialty pharmaceutical company become the largest hemophilia player and the company has announced that it has generated a revenue of more than USD 870 million in 2017.
In 2018, the global Hemophilia Gene Therapy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Hemophilia Gene Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hemophilia Gene Therapy development in United States, Europe and China.
The key players covered in this study
uniQure
Alnylam Pharmaceuticals
BioMarin Pharmaceutical
Spark Therapeutics
Shire
...
Market segment by Type, the product can be split into
Monotherapy
Combination Therapy
Market segment by Application, split into
Hemophilia A
Hemophilia B
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Hemophilia Gene Therapy status, future forecast, growth opportunity, key market and key players.
To present the Hemophilia Gene Therapy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Hemophilia Gene Therapy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
